1/1
Improving the Gastrointestinal Tolerability of Fumaric Acid Esters: Early Findings on Gastrointestinal Events with Diroximel Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis from the Phase 3, Open-Label EVOLVE-MS-1 Study
Version 2 2019-10-30, 12:46
Version 1 2019-09-09, 09:01
figure
posted on 2019-10-30, 12:46 authored by Michael J. Palte, Angela Wehr, Mark Tawa, Kristopher Perkin, Richard Leigh-Pemberton, Jerome Hanna, Catherine Miller, Natasha Penner
The above Summary Slide and Video represent the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.
